KISSEI's History

  • Aug. 1946

    Founded as Tachibana Seikagaku Institute Co., Ltd.

  • May 1947

    Corporate name changed to Kissei Yakuhin Kogyo Co., Ltd.

  • Dec. 1961

    GASCON, a gastrointestinal anti-gas agent, launched.

  • Oct. 1964

    Corporate name changed to Kissei Pharmaceutical Co., Ltd. 
    Head Office and factories constructed at present location.

  • May 1969

    Central Research Laboratories constructed.

  • Apr. 1973

    Central Research Laboratories expanded.

  • Jul. 1980

    Manufacturing Plant constructed.

  • Aug. 1982

    RIZABEN, a drug for the treatment of allergic diseases, launched.

  • Jun. 1985

    Toxicological Laboratories constructed.

  • May. 1986

    Manufacturing Plant expanded.

  • Aug. 1986

    UTEMERIN, a drug for threatened premature labor and threatened
    abortion, launched.

  • Apr. 1988

    XANBON, a drug for cerebral circulation improvement, launched.

  • Dec. 1988

    Company listed on the Second Section of the Tokyo Stock Exchange.

  • Apr. 1990

    Foodstuff Business Unit established.
    Jellix, low energy jelly, launched.

  • Nov. 1990

    Central Research Laboratories moved.

  • Apr. 1991

    BEZATOL, a drug for the treatment of hyperlipidemia, launched.

  • Sep. 1991

    Company listed on the First Section of the Tokyo Stock Exchange.

  • Dec. 1991

    Kissei Information Center constructed.

  • Mar. 1992

    Genta Soba, protein controlled soba noodles, launched.

  • May. 1992

    FRAGMIN, an anti-coagulant, launched.

  • Jun. 1992

    DOMENAN, a drug for the treatment of bronchial asthma, launched.

  • Aug. 1992

    Wholly owned Nagoya Branch building constructed.

  • May. 1993

    Matsumoto Third Drug Manufacturing Plant constructed.

  • Oct. 1994

    Shiojiri Plant constructed.Jul. 1995Tokyo Head Office established.

  • Nov. 1995

    Wholly owned Sendai Branch building constructed.
    First Quality Control Laboratory constructed.

  • Dec. 1995

    RIZABEN Eye Drops, a drug for the treatment of allergic conjunctivitis,
    launched.Aug. 199650th anniversary of the company's founding.

  • Sep. 1996

    Pharmaceutical Laboratories constructed.

  • Dec. 1996

    History of Kissei's 50 Years compiled.

  • Mar. 1997

    Tokyo Head Office(Koishikawa) established.

  • Oct. 1997

    Kissei U.S.A., Inc. subsidiary established.

  • Dec. 1997

    Wholly owned Sapporo Branch building constructed.

  • May. 1999

    Toxicological Laboratories expanded.

  • Dec. 1999

    Environmental directive established.

  • Oct. 2000

    ZOLADEX 1.8mg Depot, a drug for the treatment of endometriosis,
    launched.

  • May. 2001

    Nutritional Business Center constructed.

  • Aug. 2001

    FULSTAN, an active vitamin D3 preparation, launched.

  • Apr. 2004

    U.S.-based companies reorganized, Kissei America, Inc. established.

  • May. 2004

    GLUFAST, a drug for the treatment of type 2 diabetes, launched.

  • Mar. 2005

    Yume Series, protein controlled foods, launched.
    Macton Series, energy supply foods, launched.

  • Sep. 2005

    SALAGEN, a drug for the treatment of xerostomia, launched.

  • May. 2006

    URIEF, a drug for the treatment of dysuria associated with benign
    prostatic hyperplasia, launched.

  • Feb. 2007

    Central Research Laboratories expanded.

  • Apr. 2007

    Joetsu Chemical Laboratories constructed.

  • Dec. 2008

    New through-king i , viscosity modifier, launched.

  • Apr. 2009

    Silodosin (brand name in Japan : URIEF ), a drug for the treatment of dysuria
    associated with benign prostatic hyperplasia, launched in the US.

  • Feb. 2010

    Yume no shokutaku, assorted protein controlled frozen meal, launched.

  • Apr. 2010

    New main building of head office constructed.

  • May. 2010

    EPOETIN ALFA BS Injection, a drug for the treatment of renal anemia, launched.

  • Mar. 2011

    Genta Soy Sauce, protein controlled, low-salt soy sauce, launched.

  • Jul. 2011

    GLUBES, a drug for the treatment of type 2 diabetes,launched.

  • Aug. 2012

    Yume Bakery, protein controlled bread, launched.

  • Dec. 2013

    Genta Ponzu, protein controlled, low-salt ponzu, launched.

  • Apr. 2014

    SAVENE, a drug for the treatment of anthracycline extravasation, launched.

  • Nov. 2015

    P-TOL, a drug for the treatment of hyperphosphatemia, launched.

  • Dec. 2015

    Yume no shokutaku, 4 products of protein controlled frozen lunch, launched.

  • Jan. 2016

    URIEF OD Tab. (Orally Disintegrating Tablets), a drug for the treatment of
    dysuria associated with benign prostatic hyperplasia, launched.

  • Feb. 2016

    Nomiyasui, hydration jelly drink, launched.

  • Jun. 2016

    GLUFAST OD Tab. (Orally Disintegrating Tablets), a drug for the treatment of
    type 2 diabetes, launched.